Hipra Scientific S.L.

4 trials Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

5 Completed trials

1 Countries active

5 Unique IMPs

100% Results reported

Phase II/III

Phase II

Phase IV

Phase II/III: 1 Phase II: 2 Phase IV: 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

SARS-COV-2 VIRUS, VARIANTS B.1.351-B.1.1.7, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HETERODIMER 2 B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227) 1 PHH-1V111 1 RAXTOZINAMERAN 1

All trials

4 total

A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® LP.8.1 against SARS-CoV-2 variants. Ended

2025-524021-41-00 Phase IV 1 country PHH-1V111
A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunog… Ended

2023-508458-25-00 Phase II/III 1 country RAXTOZINAMERAN
A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with sea… Ended

2023-506189-29-00 Phase II 1 country B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, BVR-1B), A/VICTORIA/2570/201…
Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coron… Ended

2023-504639-42-00 Phase II 1 country SARS-COV-2 VIRUS, VARIANTS B.1.351-B.1.1.7, SPIKE PROTEIN, RECEPTOR BINDING DOMA…

Showing 1–4 of 4 trials

← All sponsors A–Z